Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
prostate cancer
Biotech
ESMO: A peak at Pfizer's EZH2 inhibitor flashes hope for some
An early look at Pfizer's phase 1 EZH2 inhibitor teased a benefit for prostate cancer and follicular lymphoma but not small cell lung cancer patients.
Max Bayer
Sep 11, 2022 6:00am
China's Jemincare nabs $650M biobucks pact with Genentech
Aug 18, 2022 7:08am
FDA clears AI software for spotting prostate cancer in MRI scans
Aug 8, 2022 11:01am
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets
Aug 5, 2022 7:50am
Exact Sciences sells Oncotype prostate cancer test for $30M
Aug 3, 2022 11:37am
Orion's new R&D strategy pays off with $290M Merck deal
Jul 13, 2022 10:00am
